Caristo was founded in 2018 by Cardiologists at the University of Oxford, following a decade of scientific research and technical development, and is now a leader in supporting the transformation of healthcare from treatment-based medicine to prevention. Caristo’s technology aims to revolutionise diagnosis and treatment, enabling physicians to identify patients with the highest heart attack risk and prescribe effective, personalised treatments that can prevent a fatal heart attack.
To date the company has raised a total of £10.2 million, they recently closed a successful investment round led by BGF and existing investors including Oxford Sciences Innovation (OSI), Longwall Ventures and the Oxford Technology & Innovation Fund (OTIF).
New products in the pipeline will also be capable of predicting stroke and diabetes risk, years in advance.
Business funding insights
A decade of hard work coming to fruition? Just look at our investments and exits
Far from slowing down as a result of the coronavirus pandemic, BGF’s investment activity has stepped up both in pace and volume.
Exit strategies: how to get the timing and valuation right
More than 100 BGF-backed businesses have achieved exits. Our panel of experts discuss the exit strategies that are proven to succeed.